PPARγ/RXRα-Induced and CD36-Mediated Microglial Amyloid-β Phagocytosis Results in Cognitive Improvement in Amyloid Precursor Protein/Presenilin 1 Mice

Effects of PPARγ agonist on CD36 expression in primary microglia. Primary microglia was coincubated with inhibitors of transcription [actinomycin D (ActD), 5 μm] or translation [cycloheximide (CHX), 10 μm] in the presence of FAM-Aβ (0.5 μm). After 4 h, intracellular levels of Aβ were determined. Aβ phagocytosis by DSP-8658 (A) or pioglitazone (B) was abolished by coincubation with the respective inhibitors. The data show the intracellular Aβ uptake as percentage of control (mean ± SEM of n = 3, *p < 0.05, one-way ANOVA, Tukey's post hoc test). C–E, Primary microglia was incubated with DSP-8658 or pioglitazone for 6 h, and CD36 mRNA and protein levels were detected. CD36 mRNA was upregulated in response to DSP-8658 (C) or pioglitazone (D), followed by an increase of the respective protein levels in a concentration-dependent manner (E) (mean ± SEM of n = 3, **p < 0.01, Student's t test).

CD36 mediates the PPARγ-stimulated increase in microglial Aβ uptake. Primary microglia was incubated for 4 h with either DSP-8658 (A) or pioglitazone (B; Pio) in the presence of CD36 antibody or isotype control. After 4 h, intracellular Aβ was determined. PPARγ agonist-stimulated Aβ phagocytosis was suppressed by coincubation with CD36 antibody (mean ± SEM of n = 3, *p < 0.05, **p < 0.01, ***p < 0.001, one-way ANOVA, Tukey's post hoc test). C, Protein levels of CD36 in primary microglia transfected with siRNA for CD36. D, E, Primary microglia transfected with siRNA for CD36 or nontarget were incubated with DSP-8658 or pioglitazone in the presence of FAM-labeled Aβ_1–42 (0.5 μm). After 4 h, intracellular level of Aβ was determined. Transfection of cell with CD36 siRNA blocked the PPARγ agonist-stimulated uptake of Aβ. The data show the intracellular Aβ uptake as percentage of control (mean ± SEM of n = 3, **p < 0.01, one-way ANOVA, Tukey's post hoc test).

Additive effects dual activation of PPARγ and RXR in primary microglia. Primary microglia were incubated with indicated concentrations of retinoic acid (A; RA) or bexarotene (B; BEX) in the presence of FAM-Aβ (0.5 μm). After 4 h expose to Aβ, intracellular levels of Aβ were determined. RXR agonists enhanced the uptake of Aβ in rat primary microglia in a concentration-dependent manner. The data show the intracellular Aβ uptake as percentage of control (mean ± SEM of n = 3, *p < 0.05, **p < 0.01, one-way ANOVA, Dunnett's multiple comparison test). C–F, Primary microglia was incubated with the combination of pioglitazone (0.3 μm) (C, D; Pio) or DSP-8658 (0.3 μm) (E, F) with the RXR agonists retinoic acid (10 nm) and bexarotene (1 nm) in the presence of FAM-Aβ (0.5 μm). After 4 h expose to Aβ, intracellular levels of Aβ were determined. Coincubation of PPARγ agonists with RXR agonists showed an additive enhancement on Aβ uptake. The data show the intracellular Aβ uptake as percentage of control (means ± SEM of n = 3, *p < 0.05, **p < 0.01 vs control, ^##p < 0.01 vs DSP-8658, pioglitazone, retinoic acid, or bexarotene alone, one-way ANOVA, Tukey's post hoc test).

Effects of RXRα or RXRβ suppression on Aβ phagocytosis in rat primary microglia. A, RXRα and RXRβ detection in rat primary microglia transfected with siRNA for RXRα, RXRβ, or nontarget. B, Primary microglia transfected with siRNA for RXRα or RXRβ were incubated with bexarotene (BEX) in the presence of FAM-Aβ (0.5 μm). After 4 h expose to Aβ, intracellular level of Aβ was determined. Phagocytosis was only suppressed by RXRα siRNA. The data show the intracellular Aβ uptake as percentage of control (mean ± SEM of n = 3, *p < 0.05 vs control, one-way ANOVA, Tukey's post hoc test). C, RXRα and RXRβ detection in murine primary microglia transfected with siRNA for RXRα, RXRβ, or nontarget. D, Primary murine microglia transfected with siRNA for RXRα or RXRβ were incubated with bexarotene (BEX) in the presence of FAM-Aβ (0.5 μm). After 4 h exposure to Aβ, the intracellular level of Aβ was determined. Data show the intracellular Aβ uptake as percentage of control (mean ± SEM of n = 3, *p < 0.05 vs control, one-way ANOVA, Tukey's post hoc test).

DSP-8658 induces in vivo Aβ phagocytosis and recruitment of microglia to Aβ plaques. APP/PS1 transgenic mice received either DSP-8658 or vehicle containing chow for 3 months. A, Scatter blots of CD11b⁺/CD45⁺ isolated microglia after peripheral application of methoxy-X04. Background signal was determined using wild-type (WT) control mice. General microglial background was determined by analysis of unstained, non-injected wild-type mice. B, The percentage of methoxy-X04⁺/CD11b⁺/CD45⁺ cells to CD11b⁺/CD45⁺ cells was calculated (mean ± SEM of n = 4, *p < 0.05, Student's t test). C, FACS analysis for CD36 expression was performed in non-phagocytosing (nonphago) and phagocytosing (phago) cells (mean ± SEM of n = 4, *p < 0.05, Student's t test). D, Confocal laser-scanning microscopy detected a higher number of Aβ-plaque-associated and Aβ-containing microglial cells in DSP-8658-treated APP/PS1 transgenic mice compared with vehicle-treated APP/PS1 controls. Scale bar, 50 μm. E, Colocalization of Aβ/Cd11b within microglia visualized by confocal laser-scanning microscopy. Scale bar, 5 μm. F, Ten randomly chosen plaque areas were evaluated for Aβ/Cd11b colocalization per animal (mean ± SEM of n = 4, *p < 0.05, Student's t test). G, APP/PS1 transgenic mice were treated with DSP-8658 for 3 d and injected with methoxy-X04 3 h before analysis. After isolation of microglia, CD36 expression was determined by flow cytometry in non-phagocytosing (np) and phagocytosing (p) cells. Values were normalized to the CD36 expression in untreated microglia from age-matched wild-type mice (mean ± SEM of n = 4, *p < 0.05, Student's t test). H, APP/PS1 transgenic mice were treated with DSP-8658 or bexarotene (Bex) and the combination of these compounds for 3 d. Isolated phagocytosing microglia were analyzed by FACS for CD36 expression per animal (mean ± SEM of n = 4, *p < 0.05, Student's t test).

DSP-8658 reduces Aβ burden in the APP/PS1 transgenic mice. APP/PS1 transgenic mice were treated with DSP-8658 in the diet for 3 months. After treatment, cortex and hippocampus were excised and protein was extracted. Concentrations of Aβ_1–40 and Aβ_1–42 in SDS-soluble (A, C) and RIPA-soluble (B, D) fractions from cortex and hippocampus of APP/PS1 mice were determined by sandwich ELISA. DSP-8658 reduced SDS-soluble Aβ_1–40 and Aβ_1–42 in cortex and SDS-soluble Aβ_1–42 in hippocampus compared with control (mean ± SEM of n = 4, *p < 0.05, **p < 0.01, Student's t test). E, Aβ deposition in the cortex was evaluated by thioflavin S staining and calculated as Aβ-positive area fraction (mean ± SEM of n = 4, *p < 0.05, Student's t test). Scale bar, 250 μm.